



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

DHRS13 siRNA (m): sc-143029

BACKGROUND

DHRS13 (dehydrogenase/reductase SDR family member 13), also known as UNQ419/PRO853, is a 377 amino acid secreted protein belonging to the short-chain dehydrogenases/reductases (SDR) family. DHRS13 is presumed to function as an oxidoreductase and is phosphorylated, potentially by ATM or ATR, upon DNA damage. DHRS13 exists as two isoforms produced by alternative splicing events. The gene encoding DHRS13 maps to human chromosome 17q11.2, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Neurofibromatosis, dysregulated Schwann cell growth, Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are associated with chromosome 17.

REFERENCES

1. Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E., Heldens, S., et al. 2003. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. *Genome Res.* 13: 2265-2270.
2. Song, J., Yang, W., Shih, I.e.M., Zhang, Z. and Bai, J. 2006. Identification of BCOX1, a novel gene overexpressed in breast cancer. *Biochim. Biophys. Acta* 1760: 62-69.
3. Nusbaum, R., Vogel, K.J. and Ready, K. 2006. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. *Breast Dis.* 27: 21-50.
4. Zody, M.C., Garber, M., Adams, D.J., Sharpe, T., Harrow, J., Lupski, J.R., Nicholson, C., Searle, S.M., Wilming, L., Young, S.K., Abouelleil, A., Allen, N.R., Bi, W., Bloom, T., Borowsky, M.L., Bugalter, B.E., et al. 2006. DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. *Nature* 440: 1045-1049.
5. Suela, J., Largo, C., Ferreira, B., Alvarez, S., Robledo, M., González-Neira, A., Calasanz, M.J. and Cigudosa, J.C. 2007. Neurofibromatosis 1, and not TP53, seems to be the main target of chromosome 17 deletions in *de novo* acute myeloid leukemia. *J. Clin. Oncol.* 25: 1151-1152.
6. Farrell, C.J. and Plotkin, S.R. 2007. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. *Neurol. Clin.* 25: 925-946.
7. Murakami, N., Tsuchiya, T., Kanazawa, N., Tsujino, S. and Nagai, T. 2008. Novel deletion mutation in GFAP gene in an infantile form of Alexander disease. *Pediatr. Neurol.* 38: 50-52.
8. Zhou, F.L., Zhang, W.G., Meng, X., Chen, G. and Wang, J.L. 2008. Bioinformatic analysis and identification for a novel antigen MLAA-22 in acute monocytic leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 16: 466-471.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Dhhrs13 (mouse) mapping to 11 B5.

PRODUCT

DHRS13 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see DHRS13 shRNA Plasmid (m): sc-143029-SH and DHRS13 shRNA (m) Lentiviral Particles: sc-143029-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

DHRS13 siRNA (m) is recommended for the inhibition of DHRS13 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor DHRS13 gene expression knockdown using RT-PCR Primer: DHRS13 (m)-PR: sc-143029-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.